Analysis Immunoassay of Antibody-Drug Conjugate (ADC) by KinExA (CAT#: STEM-MB-0078-CJ)

Introduction

Antibody-drug conjugates (ADC) represent a relatively new class of cancer treatments that seek to avoid the off-target toxicity associated with chemotherapy by linking a cytotoxic drug (“payload”) to a tumor reactive monoclonal antibody (mAb). Finding the ideal epitope to target is a key element for the development of an antibody-drug conjugate (ADC). The goal of this site-specific delivery method is to minimize systemic chemotherapy-associated side effects and maximize delivery of the cytotoxic agent to tumor cells. To maximize drug delivery to tumor cells and reduce side effects, this epitope should be specific to cancer cells and spare all normal tissue. Several factors such as linker properties, drug-antibody-ratio, stability and biodistribution, and drug dosing, dictate clinical success of an ADC.

Add to Cart Please Inquire

Principle Applications Procedure Materials Notes Related Products

Principle

KinExA is a two-stage analysis system. In the first stage, a number of solutions are prepared, where one partner remains constant (constant binding partner, or CBP) and the other (titrant) is variable, usually serially diluted. As the titrant is added, the free CBP decreases and is analysed by a sophisticated and precise microfluorescence measurement device. The signal generated can be mathematically related to the affinity (KD) of the two molecules for each other, as well as the kinetic parameters of binding (kon) and dissociation (koff).

Applications

Oncology & Cancer; Immunology/Inflammation; Pharmacology

Procedure

1. preparation of the functionalized beads which will capture the analyte for measuremen.
2. preparation of a series of solutions consisting of a constant initial concentration of one component of the binary reaction and serial dilutions of the other reactant. The component that is kept constant is the constant binding partner (CBP) , and is the one which will be analyzed.
3. each reaction mixture is sampled and the fluorescence of free CBP bound to the capture beads is obtained for subsequent numerical analysis.

Materials

• Sample Type: Antibodies, Cells, Small Molecules, Proteins, DNA, Lipids, Viruses, Serum, & More
• Equipment: Kinetic Exclusion Assay (KinExA)

Other recommended products

Analysis Affinity of RON Receptor Tyrosine Kinase by KinExA (CAT#: STEM-MB-0026-CJ)
Analysis Affinity of IGF-IR to IGF-I and IGF-II by KinExA (CAT#: STEM-MB-0034-CJ)
Analysis Affinity of Fabs (Mouse and Human) for Dabigatran by KinExA (CAT#: STEM-MB-0030-CJ)
Analysis Affinity and Kinetics of Prostate Specific Antigen (PSA) with Antibody M612166 by KinExA (CAT#: STEM-MB-0060-CJ)
Analysis Affinity of Clinical Anti-drug Antibody (ADA) by KinExA (CAT#: STEM-MB-0021-CJ)
Analysis Affinity of HGF and AMG 102 by Kinetic. (CAT#: STEM-MB-0005-CJ)
Analysis Affinity of Shingosine-1-Phosphate (S1P) and lysophosphatidic Acid (LPA) by KinExA (CAT#: STEM-MB-0024-CJ)
Analysis Affinity of Human mAb GNCgzk to Cocaine by KinExA (CAT#: STEM-MB-0032-CJ)